This video is featured in the 2024 ASH Annual Meeting Insights Hub

2024 ASH Annual Meeting Insights Hub
T

ASH 2024 Insights: Ven + HMA vs. HMA Alone in TP53m HR-MDS - Real-World Mayo Clinic Series

By 2024 ASH Annual Meeting Insights Hub FEATURING Talha Badar
By 2024 ASH Annual Meeting Insights Hub FEATURING Talha Badar
113 views
December 24, 2024
Comments 2
Login to view comments. Click here to Login

2024 ASH Annual Meeting Insights Hub: MDS & MPN Videos

08:34

ASH 2024 Insights: Personalized Transplant Decision Making for Myelo…

2024 ASH Annual Meeting Insights Hub

B. Mora

93 views
09:38

ASH 2024 Insights: Oral Decitabine-Cedazuridine in Pts With TP53mut …

2024 ASH Annual Meeting Insights Hub

S. Urrutia

45 views
05:46

ASH 2024 Insights: Updated Ph3 MANIFEST-2 Results - Pelabresib + Rux…

2024 ASH Annual Meeting Insights Hub

J. Mascarenhas

121 views
View All

Related Videos

25:03

ASH 2024 Summary: Highlights in AML, MDS, and ALL

2024 ASH Annual Meeting Insights Hub

T. Badar

1.3K views
21:05

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

4.8K views
15:16

ASH 2024 Summary: Transplant Options and Outcomes for TP53 Myeloid D…

2024 ASH Annual Meeting Insights Hub

H. Fernandez

265 views
25:44

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

405 views
27:49

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Insights from 2024 EHA Annual Meeting

T. Badar

832 views
27:03

ASH 2024 Review: Updates on the Management of MDS

Cleveland Clinic Taussig Cancer Institute

H. Carraway

154 views
08:29

Debate: There Is a Role for Anti-Inflammatory Treatment in MDS

MDS Foundation

L. Weeks

115 views
13:18

Cellular Therapies for Myeloid Malignancies

Moffitt Cancer Center

D. Sallman

139 views
14:32

Summary of Recent Updates in MDS

Vanderbilt University Medical Center (VUMC)

S. Ball

470 views
22:37

AML and MDS Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

T. Badar

2.2K views
05:55

ASH 2024 Insights: Secondary Heme Malignancies in Myeloma Post-CAR-T…

2024 ASH Annual Meeting Insights Hub

J. Waldschmidt

112 views
31:53

HSCT in 2024: What Every Hematologist Needs to Know

Indy Hematology Review

R. Childs

876 views
23:04

Differentiation of CHIP, ICUS, CCUS, MDS, and VEXAS Syndrome

MyCancerHaven

R. Vij, S. Abedin

278 views
24:44

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

976 views
04:16

MDS and AML: Implementation of Guideline-Driven Germline Genetic Eva…

UChicago Medicine 12th International Clinical Cancer Genomics Conference

L. Banaszak

415 views
20:58

Defining Risk of Progression in CHIP/CCUS: A Pathologists' Perspecti…

16th International Congress on Myeloproliferative Neoplasms

R. Hasserjian

108 views
08:53

Debate: There Is Not a Role for Anti-Inflammatory Treatment in MDS

MDS Foundation

L. Adès

68 views
13:26

Chronic GvHD: Main Complications After ASCT

Steven Pavletic

436 views
09:38

ASH 2024 Insights: Oral Decitabine-Cedazuridine in Pts With TP53mut …

2024 ASH Annual Meeting Insights Hub

S. Urrutia

45 views
23:37

Management of Viral Infections Post-Transplant: CMV, EBV, and HHV-6

Rush University Medical Center

E. Bhaimia

355 views
AUTOPLAY